Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs M&T Bank Corporation (MTB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs M&T Bank Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while M&T Bank Corporation trades at $240.99 (market cap $35.49B). The key difference: Alnylam Pharmaceuticals, Inc. and M&T Bank Corporation are close in size by market cap, and M&T Bank Corporation pays a 2.48% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MTB | |
|---|---|---|
Market Cap | $39.89B | $35.49B |
Sector | Health | Financials |
52-Week High | $491.22 | $242.34 |
52-Week Low | $278.09 | $178.63 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
M&T Bank (MTB) trades at $242.34, up 1.85% with a bullish technical signal. The stock shows consistent earnings beats with Q1 2026 EPS of $4.18 exceeding expectations. Fundamentals remain solid with a P/E of 13.61 and net income margin of 30.11%. Recent corporate actions include a $1.50 dividend payment scheduled for June 2026 and new board appointments supporting growth initiatives.
MTB presents a balanced investment case with strong profitability metrics and analyst consensus near current levels. The upcoming Q2 2026 earnings report on July 15 represents a key catalyst. Risks include negative cash flow trends and potential interest rate sensitivity. Institutional sentiment leans cautious with 62.5% hold ratings, suggesting measured optimism for the regional banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
